1 Recommendations
1.1
Talazoparib is recommended, within its marketing authorisation, for treating HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who have had:
-
an anthracycline or a taxane, or both, unless these treatments are not suitable, and
-
endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable.
Talazoparib is only recommended if the company provides it according to the commercial arrangement.
Why the committee made these recommendations
For most people with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA mutations, talazoparib would be used instead of chemotherapy.
Evidence from a clinical trial shows that talazoparib increases how long people live without their cancer getting worse compared with chemotherapy. But, the trial does not show any difference in how long people live.
When considering the condition's severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates for talazoparib are within the range that NICE considers an acceptable use of NHS resources. So, talazoparib is recommended.